Partner David Rosen was quoted in a Memphis Business Journal article, “A COVID-19 vaccine this year? It’s a long shot, but it’s possible,” about drug companies considering the use of a little-known regulatory tool to push their COVID-19 vaccines into Americans’ hands before the end of the year.
Rosen, who chairs the firm’s FDA regulatory practice, said the government’s decision to enact the Public Readiness and Emergency Preparedness (PREP) Act in response to the COVID-19 outbreak limits the legal repercussions that drugmakers could face if their COVID-19 products cause physical injury, death and other ill effects to users.
(Subscription required.)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”